Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

GlobeNewswire03-20

GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan").

The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the “Equity Award”) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee’s continuous service through the vesting date.

About Emergent BioSolutions

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2521499759?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-21 04:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521499759","market":"hk","top_or_hot":-1,"title":"Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08","media":"GlobeNewswire","content":"<html><body><p>GAITHERSBURG, Md., March  20, 2025  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the \"Inducement Plan\").</p> <p>The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the “Equity Award”) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee’s continuous service through the vesting date.</p> <p><strong>About Emergent BioSolutions</strong></p> <p>At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.</p> <p><strong>Investor Contact:</strong><br/>Richard S. Lindahl<br/>Executive Vice President, CFO<br/>lindahlr@ebsi.com</p> <p><strong>Media Contact:</strong><br/>Assal Hellmer<br/>Vice President, Communications<br/>mediarelations@ebsi.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MDA1NjYyZDktMTUyZi00NDQ5LTk5NzgtZmI1NDg4Zjc2MDFjLTEwMjI0MzktMjAyNS0wMy0yMC1lbg==/tiny/Emergent-Biosolutions-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2025-03-21 04:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>GAITHERSBURG, Md., March  20, 2025  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the \"Inducement Plan\").</p> <p>The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the “Equity Award”) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee’s continuous service through the vesting date.</p> <p><strong>About Emergent BioSolutions</strong></p> <p>At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.</p> <p><strong>Investor Contact:</strong><br/>Richard S. Lindahl<br/>Executive Vice President, CFO<br/>lindahlr@ebsi.com</p> <p><strong>Media Contact:</strong><br/>Assal Hellmer<br/>Vice President, Communications<br/>mediarelations@ebsi.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MDA1NjYyZDktMTUyZi00NDQ5LTk5NzgtZmI1NDg4Zjc2MDFjLTEwMjI0MzktMjAyNS0wMy0yMC1lbg==/tiny/Emergent-Biosolutions-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4215","symbol_name":"住宅房地产投资信托","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046739/33240/en/Emergent-BioSolutions-New-Hire-Equity-Grant-Under-NYSE-Rule-303A-08.html","article_id":"2521499759","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521499759","pubTimestamp":1742502600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"GAITHERSBURG, Md., March  20, 2025  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4215":"住宅房地产投资信托","EQR":"资产住宅公司","EBS":"Emergent Biosolutions","BK4585":"ETF&股票定投概念","BK4139":"生物科技","NYSE":"纽交所","BK4583":"猴痘概念","BK4588":"碎股"},"translate_title":"Emergent BioSolutions根据纽约证券交易所规则303A.08授予新员工股权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":1,"EQR":1,"NYSE":1},"content_text":"GAITHERSBURG, Md., March  20, 2025  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the \"Inducement Plan\"). The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the “Equity Award”) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee’s continuous service through the vesting date. About Emergent BioSolutions At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Investor Contact:Richard S. LindahlExecutive Vice President, CFOlindahlr@ebsi.com Media Contact:Assal HellmerVice President, Communicationsmediarelations@ebsi.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2521499759"}